Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 10/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 7/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 5/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 5/20 | 1.00 |
| ▸ | CCND3 | P30281 | 4/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL31702788 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29777523 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL291157 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290572 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665749 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL23683025 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL17348307 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL663219 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29387962 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290347 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1055 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076952-A1 | Agent for Treatment of Neutropenia | UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2026-03-19 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4683632-A1 | A CYCLIN-DEPENDENT KINASE 2/4/9 INHIBITOR FOR THE TREATMENT OF NEUTROPENIA | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| US-12350276-B2 | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | CELCUITY INC. (US) | 2025-07-08 | — | — | US | claimed |
| US-20250144054-A1 | SMALL MOLECULE STAT3 INHIBITOR FOR TREATING TRIPLE NEGATIVE BREAST CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-05-08 | — | — | US | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | claimed |
| WO-2008139271-A2 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-11-20 | — | — | WO | claimed |
| EP-1556375-B1 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LTD (IN) | 2008-06-25 | — | — | EP | claimed |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2008-05-08 | — | — | US | claimed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | claimed |
| US-7271193-B2 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA, LTD. (IN) | 2007-09-18 | — | — | US | claimed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | claimed |
| EP-1556375-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | Nicholas Piramal India Limited (IN) | 2005-07-27 | — | — | EP | claimed |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-06-03 | — | — | US | claimed |
| WO-2004004632-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350276-B2 | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | CDK4, CDKN1A, CDK2 | CDK4 1/4885CDK1 9/4885CDK9 12/4885 |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | CCNK, CCNI, CDK1 | CDK4 8/4885CDK1 3/4885CDK9 35/4885 |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | CDK4 11/4885CDK1 1/4885CDK9 43/4885 |
| US-20260076952-A1 | Agent for Treatment of Neutropenia | CDKL2, CHEK1, CDK2 | CDK4 15/4885CDK1 17/4885CDK9 6/4885 |
| US-20250144054-A1 | SMALL MOLECULE STAT3 INHIBITOR FOR TREATING TRIPLE NEGATIVE BREAST CANCER | STAT3, STAT5B, CDK12 | CDK4 12/4885CDK1 32/4885CDK9 54/4885 |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | CCNI, CDK1, CCNA1 | CDK4 7/4885CDK1 2/4885CDK9 51/4885 |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | TP53, HAVCR2, PDCD1LG2 | CDK4 538/4885CDK1 2506/4885CDK9 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.